Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?
- PMID: 24682115
- DOI: 10.1038/ki.2013.506
Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical